• Ionis completed enrollment in the pivotal pediatric cohort of its Phase 3 REVEAL trial of obudanersen in Angelman syndrome.
• The cohort enrolled 136 participants ages 2 to under 18 with UBE3A deletion or mutation; topline data expected in 2H 2027.
• Adult cohort enrollment is expected to finish in Q3 2026; REVEAL targets about 158 total participants.
• Phase 3 CHAMPION study in other Angelman genotypes remains on track to start before end-2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ionis Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202607060700BIZWIRE_USPR_____20260706_BW516467) on July 06, 2026, and is solely responsible for the information contained therein.